Hence, the meta‐analysis by Li et al., recently substantiated the significant decrease in overall mortality for patients with pathogenic BRCA1 or BRCA2 variants undergoing contralateral prophylactic mastectomy as part of the standard breast cancer intervention. This evidence concerns the gene BRCA2 and breast cancer.